GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
Systematic review shows high prevalence of covert cerebrovascular changes in schizophrenia patients compared to controls
Brain scans show hidden vessel changes in many people with schizophrenia
This systematic review and meta-analysis evaluated 11,611 patients with schizophrenia and controls from international and Chinese databases.…
A large review found hidden signs of blood vessel issues in many people with schizophrenia, though experts urge caution before drawing firm …
Meta-analysis finds decreased GDNF levels in bipolar disorder but high heterogeneity limits conclusions
Brain chemical levels differ in bipolar disorder compared to healthy people
This meta-analysis of 825 patients with bipolar disorder (BD) and 885 healthy controls found significantly lower circulating GDNF levels in …
A large review found lower levels of a specific brain chemical in people with bipolar disorder. This difference was clear even when comparin…
Cariprazine showed modest weight reduction versus aripiprazole in schizophrenia patients previously treated with olanzapine.
Cariprazine shows modest weight benefit over aripiprazole in schizophrenia patients
This trial compared cariprazine to aripiprazole in patients with schizophrenia who had previously used olanzapine. While both groups improve…
A trial found cariprazine linked to slightly more weight loss than aripiprazole in people with schizophrenia, though overall differences wer…
Meta-analysis reviews psychosis prevalence in bipolar disorder patients across 285 studies
Psychosis common in bipolar disorder, review finds
This meta-analysis reviews data from 285 studies regarding the prevalence of psychosis and psychotic symptoms in patients with bipolar disor…
Nearly half of people with bipolar disorder experience psychosis, and 8% also have schizophrenia, a review of 285 studies finds.
Diabetes and social support associations with cognitive impairment in elderly schizophrenia inpatients
Social support and daily living skills linked to lower dementia risk in schizophrenia
This retrospective cross-sectional study of 149 elderly inpatients with schizophrenia found a 47.7% prevalence of cognitive impairment. High…
Nearly half of elderly schizophrenia patients have cognitive impairment. Social support and daily living skills may protect against it.
Systematic review and meta-analysis finds 50% prevalence of antipsychotic polypharmacy in MENAT/EMRO countries
Half of Schizophrenia Patients Take Multiple Drugs at Once
This systematic review and meta-analysis of 17 studies (6,053 individuals) from MENAT/EMRO countries found a pooled prevalence of antipsycho…
New data reveals half of patients with schizophrenia in the Middle East take multiple antipsychotic drugs at once.
Longer untreated psychosis linked to less symptom improvement in first-episode schizophrenia
Shorter Untreated Psychosis Linked to Better Recovery in Schizophrenia
This cohort study of 99 first-episode schizophrenia patients found that longer duration of untreated psychosis (DUP >26 weeks) was associate…
Patients who get care sooner for first-episode schizophrenia show greater symptom improvement than those who wait longer.
FDA Approves Caplyta (lumateperone) for Schizophrenia in Adults
FDA approves Caplyta to treat schizophrenia in adults.
FDA approved Caplyta (lumateperone) for treatment of schizophrenia in adults. The approval was based on two placebo-controlled trials showin…
The FDA approved Caplyta (lumateperone) for treating schizophrenia in adults. It is a once-daily pill that works without needing to adjust t…
Narrative review explores microbiome mechanisms as a promising adjunctive avenue for managing depression, anxiety, bipolar disorder, and schizophrenia.
Gut Bacteria Can Change Your Mood
This narrative review examines how microbiome-driven modulation of neurotransmitters, microbial metabolites, immune activation, and vagal ne…
What if the bacteria in your gut could be quietly shaping how you feel every day — and fixing them could ease anxiety or depression?
Observational study identifies sensory perception differences in schizophrenia and first-episode psychosis
Simple tests reveal unique sensory signs for early psychosis types
This observational study investigated psychophysical differences in pictorial size perception and auditory discomfort among patients with sc…
New low-cost tests can spot unique sensory changes that help doctors tell schizophrenia apart from bipolar disorder in early psychosis cases…
Parental severe mental illness associated with reduced offspring cognitive and academic performance in large meta-analysis
Children of parents with mental illness face real cognitive hurdles now
This meta-analysis examined 1,586,339 offspring of parents with severe mental illnesses, including schizophrenia, bipolar disorder, and majo…
New research shows kids of parents with severe mental illness struggle with memory and thinking skills, but early help can make a big differ…